There has been plenty of state-level psychedelic policy reform activity since our last update (see: Psychedelic Policy Push Continues: Over 60 Bills Introduced Across 22 States), with nearly thirty states now deliberating some sort of legislation since the year began.

That includes a half-dozen news states that have entered 2025 psychedelic policy reform push: last month, lawmakers in Maine, Minnesota, North Carolina, Texas, and West Virginia filed psychedelics-focused bills.

As seen in previous months (see our January and February 2025 round-ups), there is great diversity in the bills introduced. These range from additional rescheduling trigger law bills that focus narrowly on pharmaceutical forms of crystalline polymorph psilocybin (e.g., Iowa SSB 1177; West Virginia HB 3343) on the more vanilla end, right through to decriminalisation or removing criminal penalties for the possession of certain psychedelics like psilocybin (e.g., Maine LD 1034; Massachusetts S 1113; Minnesota HF 2699; Vermont S 120; Vermont H 452) on the more substantive end.

We also see bills focused on establishing pilot programs (e.g., Massachusetts HD 4509; Nevada AB 378), state-regulated systems (e.g., New Jersey A 3852), task forces and working groups (e.g., New Mexico HM 58; North Carolina SB 568; Texas SB 3005; Vermont S 106), and funding streams for psychedelic research (e.g., Texas SB 2308).

At the federal level, last week saw the introduction of the Innovative Therapies Centers of Excellence Act, which aims to carve out structure and funding for psychedelic therapies access in the VA (see: Behind the Bill: Inside a Bipartisan Effort to Bring Psychedelic Therapy to Veterans). Aside from that bill, there are many conversations happening about how the new administration can support psychedelic research and roll-out at the federal level.

Still, the vast majority of on-the-record psychedelic policy deliberation is happening in state legislatures, the focus of this update. Here, Psychedelic Alpha’s Noah Smith and Josh Hardman present a state-by-state, bill-by-bill round-up of psychedelics-focused bills introduced in March.

Editor’s note: Later this week, we will publish a review of major updates on the psychedelic bills introduced thus far this year.

***

Georgia

HB 717: Regulates the Provision of FDA-Approved Psychedelic-Assisted Treatments

This bill, introduced by a bipartisan suite of state Representatives, would amend Georgia law to allow psychedelic-assisted treatment and therapy to be provided by certain licensed healthcare professionals, once FDA approved.

HB 717 envisages the creation of a Board which would be tasked with establishing rules and regulations to govern the administration of psychedelic-assisted treatment in clinics by the end of 2025. The Bill identifies physicians (general), anaesthesia assistants, and certified RN anaesthetists as those professionals who are appropriate to oversee and/or deliver such treatments.

Once the Board has arrived at its rules and recommendations, licenses will be issued from July 1, 2026, according to the Bill’s current text, with applications for licensure reviewed by the Board.

While the Bill discusses “psychedelic-assisted treatment”, the scope of drugs included within its provisions is limited to those that are FDA-approved. For now, then, that only includes ketamine, but there would be room for expansion to other agents once approved...